Evidence map›Paper›PMID 40654658›Full record

ArticlebioRxiv : the preprint server for biology2025

Classification of outcomes in antimalarial therapeutic efficacy studies with Aster.

Inna Gerlovina, Sophie Berube, Jessica Briggs, Kathryn Murie, Maxwell Murphy, Amy Wesolowski, Bryan Greenhouse

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Inna GerlovinaEPPIcenter research program, Division of HIV, ID and Global Medicine, Department of Medicine, University of California, San Francisco, CA, USA.ORCID 0000-0002-7772-7473
Sophie BerubeDept of Biostatistics, University of Florida, Gainesville, FL, USA.
Jessica BriggsEPPIcenter research program, Division of HIV, ID and Global Medicine, Department of Medicine, University of California, San Francisco, CA, USA.
Kathryn MurieEPPIcenter research program, Division of HIV, ID and Global Medicine, Department of Medicine, University of California, San Francisco, CA, USA.
Maxwell MurphyEPPIcenter research program, Division of HIV, ID and Global Medicine, Department of Medicine, University of California, San Francisco, CA, USA.
Amy WesolowskiDept of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Bryan GreenhouseEPPIcenter research program, Division of HIV, ID and Global Medicine, Department of Medicine, University of California, San Francisco, CA, USA.

Funding

Mentoring translational scientists in international infectious disease researchK24AI144048 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bryan R Greenhouse · 2019 to 2026
$1.6M
Data and analysis ecosystem for eukaryotic pathogen targeted sequencingU01AI184646 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GREENHOUSE, BRYAN R · 2024 to 2025
$1.5M
NIAID NIH HHS K24 AI144048NIAID NIH HHS U01 AI184646
6 · The paper itself

Abstract

Reliable assessment of antimalarial drug efficacy is crucial for effective response to emerging drug resistance, and therapeutic efficacy studies (TES) are the primary means of estimating

Identifiers

PMID40654658
PMCPMC12247718

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.